{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:41:15Z","timestamp":1761741675347,"version":"build-2065373602"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Gaucher disease (GD) type I is a rare lysosomal storage disorder characterized by systemic manifestations including hepatosplenomegaly, cytopenias, and skeletal complications. Although liver involvement is common, its clinical significance and diagnostic potential remain underexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To analyze the spectrum of liver involvement in Ukrainian patients with type I Gaucher disease and to evaluate its clinical, biochemical, and diagnostic significance throughout the course of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed medical records of 89 patients with confirmed GD who were monitored at the National Children\u2019s Specialized Hospital \u201cOkhmatdyt\u201d (Kyiv, Ukraine) between 2001 and 2023. Type I Gaucher was confirmed in 82 patients. Diagnosis was established through enzymatic and molecular genetic testing. Liver enlargement, hepatic structural changes, laboratory markers, ultrasound findings, and serum ferritin levels were assessed, with comparative analysis between patients with and without splenectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Hepatomegaly was observed in 91% of patients with GD type I. Despite liver enlargement, only 2.4% of patients demonstrated elevated transaminases, and no hyperbilirubinemia was reported, indicating preserved hepatic function. Additional liver pathology (steatosis, fibrosis, hemangiomatosis, cysts, or cholecystitis) was present in 45% of cases. A strong correlation was identified between the degree of hepatomegaly and elevated ferritin levels. Cholelithiasis was significantly more prevalent among splenectomized patients (42% vs. 17%; OR = 4.25;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.014).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Liver involvement in GD type I is common, multifaceted, and may not always be reflected in standard liver function tests. While hepatocellular function is typically preserved, structural liver abnormalities are frequently observed. Serum ferritin may serve as an auxiliary marker of disease activity. The results emphasize the need for comprehensive hepatic monitoring in GD and support the potential value of neonatal screening for early detection and management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1610755","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:08:46Z","timestamp":1761721726000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Liver involvement in Gaucher disease type I: a retrospective single-center study from Ukraine"],"prefix":"10.3389","volume":"12","author":[{"given":"Nataliia","family":"Samonenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataliia","family":"Olkhovych","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olena","family":"Okhotnikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataliia","family":"Gorovenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ajh.21888","article-title":"A reappraisal of Gaucher disease-diagnosis and disease management algorithms.","volume":"86","author":"Mistry","year":"2011","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases.","volume":"4","author":"Platt","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B3","article-title":"Gaucher disease.","author":"Hughes","year":"2023","journal-title":"GeneReviews<sup>\u00ae<\/sup>."},{"key":"B4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13023-023-02760-z","article-title":"GAU-PED study for early diagnosis of Gaucher disease in children with splenomegaly and cytopenia.","volume":"18","author":"Pession","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000489251","article-title":"Gaucher disease and myelofibrosis: a combined disease or a misdiagnosis?","volume":"139","author":"Mariani","year":"2018","journal-title":"Acta Haematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2022.03.001","article-title":"The diagnosis and management of Gaucher disease in pediatric patients: where do we go from here?","volume":"136","author":"Weinreb","year":"2022","journal-title":"Mol Genet Metab."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.3390\/diagnostics14242840","article-title":"An overview of Gaucher disease: diagnosis, management and outcomes.","volume":"14","author":"M\u00e9ndez-Cobi\u00e1n","year":"2024","journal-title":"Diagnostics."},{"key":"B8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bcmd.2016.10.001","article-title":"Liver involvement in Gaucher disease \u2013 Review and clinical approach.","volume":"68","author":"Adar","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The gaucher registry: demographics and disease characteristics of 1698 patients with gaucher disease.","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch Intern Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"100564","DOI":"10.1016\/j.ymgmr.2019.100564","article-title":"Liver involvement in patients with Gaucher disease types I and III.","volume":"22","author":"Starosta","year":"2020","journal-title":"Mol Genet Metab Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ajh.21721","article-title":"Hyperferritinemia and iron overload in type 1 Gaucher disease.","volume":"85","author":"Stein","year":"2010","journal-title":"Am J Hematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/qjmed\/93.4.237","article-title":"Massive hepatic fibrosis in Gaucher\u2019s disease: clinico-pathological and radiological features.","volume":"93","author":"Lachmann","year":"2000","journal-title":"QJM"},{"key":"B13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/bjs.1800570318","article-title":"Gaucher\u2019s disease and portal hypertension.","volume":"57","author":"Sales","year":"1970","journal-title":"Br J Surg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.7124\/bc.000949","article-title":"Analysis of mutations in GBA gene in Ukrainian patients with Gaucher disease.","volume":"33","author":"Olkhovych","year":"2017","journal-title":"Biopolym Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/00004836-200408000-00009","article-title":"Increased prevalence of cholelithiasis in gaucher disease.","volume":"38","author":"Ben Harosh-Katz","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10545-010-9070-1","article-title":"High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease.","volume":"33","author":"Taddei","year":"2010","journal-title":"J Inherit Metab Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.15403\/jgld.2014.1121.254.zim","article-title":"Cholelithiasis in patients with Gaucher disease type 1: risk factors and the role of ABCG5\/ABCG8 gene variants.","volume":"25","author":"Zimmermann","year":"2016","journal-title":"J Gastrointestin Liver Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1111\/liv.14640","article-title":"Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease.","volume":"40","author":"Nascimbeni","year":"2020","journal-title":"Liver Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1111\/liv.14640","article-title":"Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease.","volume":"40","author":"Nascimbeni","year":"2020","journal-title":"Liver Int"},{"key":"B20","doi-asserted-by":"publisher","first-page":"109010","DOI":"10.1016\/j.ymgme.2025.109010","article-title":"Predicting liver fibrosis in Gaucher disease.","volume":"144","author":"Starosta","year":"2025","journal-title":"Mol Genet Metab."},{"key":"B21","doi-asserted-by":"publisher","first-page":"9912","DOI":"10.3390\/ijms22189912","article-title":"C5a activates a pro-inflammatory gene expression profile in human gaucher iPSC-Derived macrophages.","volume":"22","author":"Serfecz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.dld.2020.01.004","article-title":"Liver involvement in Gaucher disease: a practical review for the hepatologist and the gastroenterologist.","volume":"52","author":"Carubbi","year":"2020","journal-title":"Dig Liver Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/children10050869","article-title":"Pediatric Gaucher disease presenting with massive splenomegaly and hepatic gaucheroma.","volume":"10","author":"Boss\u00fa","year":"2023","journal-title":"Children (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.ymgme.2017.12.370","article-title":"Gaucheroma mimicking hepatocellular carcinoma in a cirrhotic type I Gaucher disease patient [abstract]","volume":"123","author":"Starosta","year":"2018","journal-title":"Mol Genet Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/8904_2016_562","article-title":"Rare case of hepatic gaucheroma in a child on enzyme replacement therapy.","volume":"32","author":"Korula","year":"2017","journal-title":"JIMD Rep"},{"key":"B26","year":"2023","journal-title":"\u0423\u043d\u0456\u0444\u0456\u043a\u043e\u0432\u0430\u043d\u0438\u0439 \u043a\u043b\u0456\u043d\u0456\u0447\u043d\u0438\u0439 \u043f\u0440\u043e\u0442\u043e\u043a\u043e\u043b \u043f\u0435\u0440\u0432\u0438\u043d\u043d\u043e\u0457 \u0442\u0430 \u0441\u043f\u0435\u0446\u0456\u0430\u043b\u0456\u0437\u043e\u0432\u0430\u043d\u043e\u0457 \u043c\u0435\u0434\u0438\u0447\u043d\u043e\u0457 \u0434\u043e\u043f\u043e\u043c\u043e\u0433\u0438 \u00ab\u0425\u0432\u043e\u0440\u043e\u0431\u0430 \u0413\u043e\u0448\u0435\u00bb [Unified clinical protocol of primary and specialized medical care \u201cGaucher\u2019s disease\u201d]."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJM199212033272304","article-title":"A less costly regimen of alglucerase to treat Gaucher\u2019s disease.","volume":"327","author":"Figueroa","year":"1992","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.3390\/jcm13123588","article-title":"Twelve years of the Gaucher outcomes survey (GOS): insights, achievements, and lessons learned from a global patient registry.","volume":"13","author":"Elstein","year":"2024","journal-title":"J Clin Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.22088\/IJMCM.BUMS.12.1.40","article-title":"Mutational analysis and genotype investigation of less known Gaucher mutations through haplotype analysis in Iranian Gaucher patients.","volume":"12","author":"Sardarpour","year":"2023","journal-title":"Int J Mol Cell Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"102677","DOI":"10.1016\/j.clinre.2025.102677","article-title":"Multiorgan fibrosis in Gaucher disease type I: an unmet goal of enzyme replacement therapy.","volume":"49","author":"Hexner-Erlichman","year":"2025","journal-title":"Clin Res Hepatol Gastroenterol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1610755\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:08:50Z","timestamp":1761721730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1610755\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":30,"alternative-id":["10.3389\/fmed.2025.1610755"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1610755","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"article-number":"1610755"}}